Dosing has commenced in HMNC Brain Health and Develco Pharma’s Phase 2 oral prolonged-release Ketamine (KET01) Study The trial will assess the efficacy,.
Appointment accelerates Company's development roadmap in targeted therapies for neuropsychiatric disorders The Head of the Statistical Genetics Research Group at Max-Planck-Institute of Psychiatry
HMNC Holding GmbH: HMNC Brain Health to Participate in H.C. Wainwright Bioconnect Conference in January 2022 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.